Ovid Therapeutics Inc. (NASDAQ: OVID) reported favorable safety and tolerability results from a 7 mg dose of its experimental epilepsy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE